NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today it has purchased patents for its innovative stem cell production technology from the Technion-Israel Institute of Technology (Technion) and the Weizmann Institute of Science (Weizmann) for approximately $2 million. The purchased patents replace a previous license agreement with Technion and Weizmann where Pluristem had exclusive rights to the technology in exchange for royalties.
